Yuqiu Jiang

发表

Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions

Yixin Wang, D. Talantov, Jack X. Yu, 2005, Clinical Cancer Research.

Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

D. Ruderman, M. Gross, Yixin Wang, 2013, The Prostate.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

S. Loi, H. Iwata, A. DeMichele, 2016, The Lancet. Oncology.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

M. Gross, Yixin Wang, D. Agus, 2010, Clinical chemistry.

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

T. Chou, C. Chiu, Chun-Ming Tsai, 2022, PloS one.

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

D. Gandara, S. Yaung, D. Shames, 2021, JCO precision oncology.

Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes.

S. Reed, Angela Bennington, R. Houghton, 2002, Clinical chemistry.

Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays

Yuqiu Jiang, Roberto Badaro, S. Reed, 2002, Oncogene.

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

G. Curigliano, P. LoRusso, K. Kern, 2016, Oncotarget.

Clonal Hematopoiesis in Late-Stage Non–Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing

S. Yaung, Yuqiu Jiang, N. Patil, 2020 .

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine

A. Chaudhuri, M. Mutch, R. Fields, 2021, JCO precision oncology.

Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.

Marek Skacel, Graham Casey, Yi Zhang, 2008, The Journal of molecular diagnostics : JMD.

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue

S. Sleijfer, J. Foekens, Yixin Wang, 2013, International journal of cancer.

Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes.

S. Yaung, Yuqiu Jiang, N. Patil, 2019, Journal of Clinical Oncology.

Personalized medicine in oncology: tailoring the right drug to the right patient.

Yuqiu Jiang, Mu Wang, Yuqiu Jiang, 2010, Biomarkers in medicine.

Novel Genes AssociatedwithMalignantMelanoma but not BenignMelanocytic Lesions

Yixin Wang, D. Talantov, D. Atkins, 2005 .

P704P, P712P, and P775P: A genomic cluster of prostate‐specific genes

S. Reed, R. Houghton, Jiangchun Xu, 2004, The Prostate.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

R. Vij, S. Singhal, S. Ely, 2015, Leukemia & lymphoma.

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

K. Gelmon, H. Rugo, R. Finn, 2016 .

Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).

G. Curigliano, P. LoRusso, K. Kern, 2015 .

Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).

S. Loi, S. Loibl, F. André, 2016 .

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue

S. Sleijfer, J. Foekens, Yixin Wang, 2013, International journal of cancer.

Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.

Elena A. Manilich, Yixin Wang, Yi Zhang, 2008, Journal of Molecular Diagnostics.